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Case Report

Renal Granulomatosis Post Intravesical Bacillus Calmette-Guerin
Therapy for Non-muscle-invasive Bladder Cancer
Karen Tran-Harding, Rashmi T Nail; Halemane Ganesh
Department of Diagnostic
Radiology, University of
Kentucky Chandler Medical
Center, Lexington, KY, USA

~

Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is a proven,
effective treatment for intennediate- and high-risk non-muscle-invasive bladder
~ cancer. Minor side effects are common and expected but systemic effects can
~ occur in <5% of treated patients. We present a rare case of a 49-yea.r-old male
that presented with fever and chills after 3 weeks of intravesical BCG therapy
post transurethral resection of bladder tumor. New renal lesions were present on
contrast-enhanced computed tomography scan which was histologically proven to
be necrotizing renal granulomatosis.
~
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CASE REPORT

ff or over 40 years intravesical BCG has been the gold
J standard treatment for intennediate- and high-risk

Our patient is a 49-year-old male with a histmy of
high-grade Tl urothelial cell carcinoma of the bladder who
underwent induction Bacillus Calmette-Guerin (BCG)
immunotherapy, and repeat biopsies of the bladder
which were negative. Smveillance with a computed
tomography (CT) urogram demonstrated a suspicious
nodular focus along the tight lateral wall of the bladder.
Subsequent two office cystoscopies demonstrated no
evidence of tumor recurrence or abnonnalities. The
patient, however, later underwent paitial cystectomy
2 months later where the pathology was negative for
malignancy. Repeat bladder biopsies 8 months after
surgery revealed urothelial CIS. The patient elected
to undergo a second induction course of BCG. After
completing 4 of the 6 treatments, the patient developed
low-grade fever/chills and low back pain and was
seen in the emergency department. Contrast-enhanced
CT (CECT) scan of the abdomen which was petfonned
as part of the workup showed a roughly 2 cm mass-like

non-muscle-invasive bladder cancer (NMIBC) after
transurethral bladder resection.Pl BCG is an attenuated
live strain of Mycobacterium bm is, and although its
mechanism of action is not completely understood, it is
believed that the treatment works through an immune
response and a direct tumor response.[21
Adjuvant BCG is highly effective in reducing
the risk of recurrence of high-grade NMIBC
by up to 70% compared with transurethral
resection.!31 For carcinoma in situ (CIS), BCG has
been shown to generate a complete response in
up to 70%--90% of cases_[4 J Minor toxic reactions
such as urinaiy frequency, urgency, dysuria, and
hematuria have been reported in 27%- 90% of the
patientsYJ Granulomatous complications are very
uncommon and include entities such as prostatitis,
epididymo-orchitis, cystitis, pyelonephritis, and
abscessesYl The incidence of significant renal
complications is significantly less and varies from
0.2% to 2% with renal granulomatosis occmTing in
0.1% of treated patientsYl We report a rare case of
renal granulomas seen on imaging post intravesical
BCG therapy for NMIBC .
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area in the lower pole of the right kidney with moderate
perinephric inflammatory changes [Figme la and b].
Smaller subcentin1eter ill-defined hypodense foci were
also seen. A primaiy renal mass was suspected, and a
repeat CECT scan pe1fo1med 3 weeks later demonstrated
a persistent mas -like hypodense lesion in the light kidney
with significantly improved perinephric inflammat01y
changes [Figure 2a and b]. The differential included
infection or inflammation. PrimaIY renal malignancies
such as renal cell carcinoma and mothelial cell carcinoma
and infiltrative masses such as lymphoma continued to
be the main suspicions, and a CT-guided biopsy was
recommended for histological confimrntion [Figure 3a].
Histopathology confirmed marked chronic inflammation
and necrotizing granulomas without evidence for

malignancy [Figure 3b]. The primaiy clinical team
decided to manage the patient conservatively with close
follow-up due to resolution of the symptoms. Altl10ugh
antituberculous therapies are instituted in ome cases
there continue to be a lack of consensus regaI·ding
approp1iate management of renal granulomatosis. The
patient then finished his fifth instillation of BCG. Eight
months later, a CECT scan showed inte1val resolution
of the right renal lesions with mild residual co1tical
scarring [Figure 4a and b]. On repeat cystoscopy and
biopsy 8 months later, the patient was noted to have
recunent non-invasive high-grade papillfilY urothelial
cell caI·cinoma. The patient has since had a radical
cystectomy with ileal conduit urinaiy diversion.
DISCUSSION

Intravesical BCG has proven to be an effective treatment
for intermediate- and high-risk NMIBC.£ 11 High-risk

Figure 1: A 49-year-old male with a history ofhigh-grade Tl urothelial cell
carcinoma of the bladder undergoing induction bacillus Calmette--Guerin
immunotherapy. Initial presentation with fevers and chills after 3 weeks
(4 of 6 treatments) of intravesical bacillus Calmette--Guerin therapy.
(a) Axial contrast-enhanced computed tomography scan of the abdomen
through the level of the kidney showing mass-like low attenuation
lesion (yellow star) in the interpolar region of the right kidney with
moderate surrounding perinephric inflammatory changes (blue arrow).
(b) Coronal reformat contrast-enhanced computed tomography scan
of the abdomen and pelvis showing mass-like low attenuation lesion
(yellow star) in the interpolar region of the right kidney with moderate
surrounding perinephric inflammatory changes (blue arrow). There is
also mild diffuse bladder wall thickening (red arrow).

Figure 3: A 49-year-old male with a history of high-grade Tl
urothelial cell carcinoma of the bladder undergoing induction bacillus
Calmette--Ouerin immunotherapy. Initial presentation with fevers
and chills after 3 weeks (4 of 6 treatments) of intravesical Bacillus
Calmette-Guerin therapy. (a)Axial computed tomography of the abdomen
through the level of the kidneys demonstrates a percutaneous computed
tomography-guided biopsy of the lesion (blue circle). (b) Core needle
biopsy from right renal mass showing marked chronic inflammation
with granulomas (red circles). Special stains for acid-fast bacilli (Fite)
and fungi (GMS) were negative (not shown).

Journal of Clinical Imaging Science : Volume 8 : 2018

Figure 2: A 49-year-oldmale with a history ofhigh-grade Tl urothelial cell
carcinoma of the bladder undergoing induction bacillus Calmette--Guerin
immunotherapy. Initial presentation with fevers and chills after 3 weeks
(4 of 6 treatments) of intravesical bacillus Calmette--Guerin therapy.
(a) Axial contrast-enhanced computed tomography of the abdomen
through the level of the kidneys shows low attenuation lesions
(yellow star) in the interpolar region of the right kidney with improving
perinephric inflammatory changes 3 weeks later (blue arrow). (b) Coronal
reformat contrast-enhanced computed tomography scan through the
abdomen showing low attenuation lesions (yellow star) in the interpolar
region of the right kidney with improving perinephric inflammatory
changes 3 weeks later (blue arrow).

Figure 4: A 49-year-old male with a history ofhigh-grade Tl urothelial cell
carcinoma of the bladder undergoing induction bacillus Calmette--Guerin
immunotherapy. Initial presentation with fevers and chills after
3 weeks (4 of 6 treatments) of intravesical bacillus Calmette--Guerin
therapy. (a) Axial contrast-enhanced computed tomography scan of the
abdomen through the level of the kidneys showing interval resolution
of the right renal lesions with mild residual cortical scarring 8 months
later (blue arrow). (b) Coronal reformat contrast-enhanced computed
tomography scan showing interval resolution of the right renal lesions
with mild residual cortical scarring 8 months later (blue arrow).
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NMIBC is defined as any transitional cell carcinoma
of the bladder with high-grade papillaiy stage Ta or Tl
tumors and any patient with CIS.Pl BCG immunotherapy
treatment is scheduled for patients that have had a
complete transurethral resection of tumor and consists
of once weekly inte1val treatment for a total of six
treatments.Pl
The definition of BCG failure includes high-grade
tumor recurrence.Pl Patients considered to be the
highest risk are more likely to fail BCG treatment and
ai·e recommended an early cystectomy as in the case
with our patient.r6J BCG is usually well tolerated with
severe systemic complications only occun"ing in <5% of
patients.r7J It is debatable whether the complications result
from a form of hypersensitivity reaction or an active
mycobacterial infection.Pl Minor reactions ai·e usually
mild, transient, and easily managed. Flu-like symptoms
occur in patients within the first 24-48 h following
intravesical instillation and are usually explained by the
inflammatory reaction niggered by the BCG.[7) IlTitative
lower m"inaiy u·act symptoms and gross hematuria ai·e
also common and usually occur after third instillation.[41
A single-dose of quinolone 6 h after instillation might
decrease side effects and improve tolerability for minor
reactions.[7) Other rare systemic complications include
granulomatous reactions, pneumonitis and/or hepatitis,
aithralgia, epididymitis, sepsis, rash, ureteral obsuuction,
conu·acted bladder, renal abscess, and cytopenia.[41
Severe complications can be prevented by careful patient
selection and safe adminisu·ation practices. Treatment
of severe complications can require antituberculous
medications for 3-o months.[7)
The incidence of renal toxicity from BCG is
anywhere from 0.2% to 2% with the development of
a granulomatous renal mass occurring in <0.1 % of
patients.r5.s1 In some rep01ts, renal disease presented as
pyelonephtitis after the third or fourth instillation doses.
It can also present as flank pain or urinaiy frequency.rs1
Other patients such as in our case present with features of
renal mass.rs1It has been hypothesized that renal affliction
by BCG therapy may be related to vesicoureteral reflux
that commonly occurs after transuretht·al resection of
bladder tmnor.r91
Imaging of post intravesical therapy, BCG granulomas
can present as enhancing lesions on CECT scans)5J Renal
manifestations may include pyelonephtitis or abscesses
with a segmental disu·ibution and pe1fuepht·ic su·anding) 81
Some may even mimic expansile masses or present as
multiple hypodense lesions with the kidney)5J A "central
unaffected calyx sign" has been described that shows
BCG granulomatosis as a solid mass in the kidney
with a normal calyx centrally.P 01 The main differential

considerations would, however, include primaiy renal
neoplasms such as renal cell cai·cinoma or infilu·ative
conditions such as lymphoma or leukemia Imaging
can be quite inconclusive in the vast majotity of the
cases of renal granulomatosis such as in our case
especially given the extremely low incidence of the
condition. It would be pmdent to obtain histological
confi1mation by image-guided percutaneous biopsy
if there is no convincing improvement on subsequent
follow-up imaging. Once confirmed, renal granulomas
may be u·eated with rifainpin and isoniazid for
3- 6 months.rs1 Sometimes, no treatment is undertaken
and these granulomas tend resolve spontaneously as m
our case. rs1
CONCLUSION

BCG is the gold standai·d therapy for NMIBC. Although
it is usually well tolerated, a small number of patients
can have systemic side effects. As renal granulomas
though can present in a vatiety of different ways, it is
essential to have high clinical suspicion to consider
post BCG treatment reaction as a possible differential
diagnosis. This case demonstrates the pmdence of
strict follow-up imaging so that prompt therapy can be
initiated when necessaiy while the renal lesions are still
asymptomatic. Although extremely rare, recognition of
imaging findings of renal granulomas with an appropriate
history is imp01tant to distinguish it from a primaiy renal
or metastatic neoplastic process to avoid unnecessaiy
surgical procedures and to prese1ve renal parenchyma.
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